A study reported in Nature Cancer found pancreatic tumors can evade ferroptosis and resist chemotherapy by using a previously identified protein modification strategy. The work connects tumor survival under gemcitabine pressure to specific molecular circuitry rather than general stress-resistance explanations. In another cancer biology item, researchers tied chronic interferon II exposure to immunosuppression in cancer via mitochondrial dysfunction pathways. The findings were published in Science and outline how interferons can flip from anti-tumor engagement to pro-tumor support. Both studies strengthen the mechanistic basis for next-generation combination strategies—either by removing ferroptosis escape routes or by preventing immune-supporting mitochondrial/IFN remodeling.